Efavirenz 600 mg Tab
Efavirenz 600 mg Tablets are a non-nucleoside reverse transcriptase inhibitor formulated for once-daily administration, playing an established role in combination antiretroviral regimens for the long-term management of HIV-1 infection under recommended treatment protocols.
Product Details
Therapeutic Class
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
600 mg once daily, preferably at bedtime, or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
30 tablets
Efavirenz 600 mg Tab
Efavirenz 600 mg Tablets are a non-nucleoside reverse transcriptase inhibitor formulated for once-daily administration, playing an established role in combination antiretroviral regimens for the long-term management of HIV-1 infection under recommended treatment protocols.
Product Details
Therapeutic Class
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
600 mg once daily, preferably at bedtime, or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
30 tablets
Efavirenz 600 mg Tab
Efavirenz 600 mg Tablets are a non-nucleoside reverse transcriptase inhibitor formulated for once-daily administration, playing an established role in combination antiretroviral regimens for the long-term management of HIV-1 infection under recommended treatment protocols.
Product Details
Therapeutic Class
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
600 mg once daily, preferably at bedtime, or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
30 tablets